Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Inozyme Pharma Inc
(NQ:
INZY
)
5.400
+0.290 (+5.68%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Inozyme Pharma Inc
< Previous
1
2
Next >
Inozyme Pharma, Inc. Announces Pricing of Public Offering of Common Stock
July 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma, Inc. Announces Proposed Offering of Common Stock
July 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Updates on Global Development Strategy of INZ-701 for the Treatment of ENPP1 Deficiency
July 26, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Provide ENPP1 Deficiency Program Update on July 26, 2023
July 19, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Dosing of First Infant with ENPP1 Deficiency in a Phase 1b Trial of INZ-701
June 27, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present at the Jefferies Healthcare Conference
June 02, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports First Quarter 2023 Financial Results and Provides Business Highlights
May 09, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Present Recently Announced Preliminary Data from Ongoing Phase 1/2 Trial in ENPP1 Deficiency at the European Calcified Tissue Society Congress (ECTS)
April 14, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference
April 11, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Operations Officer
April 04, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Full Year 2022 Financial Results and Provides Business Highlights
March 22, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in the Cowen 43rd Annual Health Care Conference
March 01, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701
February 16, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Host Virtual Investor and Analyst Event on Feb. 16, 2023
February 06, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Investor and Analyst Event and Highlights 2022 Progress
January 09, 2023
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Peer-Reviewed Publication Revealing Increased Prevalence of ENPP1 Deficiency
December 05, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate at the BofA Securities Biotech SMID Cap Conference
December 01, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Reports Third Quarter 2022 Financial Results and Provides Business Updates
November 10, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma to Participate in Upcoming Investor Conferences
November 07, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces First Self-Administration of INZ-701 in Ongoing ENPP1 Deficiency Phase 1/2 Clinical Trial
November 03, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
Inozyme Pharma Announces Publication of Comprehensive ENPP1 Variant Database
October 31, 2022
From
Inozyme Pharma Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.